KOHEN AVOCATS · PARIS, FRANCE
Propranolol Extended Release Capsules Metal Recall: Should You Keep Taking Them and What Are Your Rights?

Hassan Kohen is a Paris-based lawyer admitted to the Paris Bar (Avocat au Barreau de Paris). Initial strategic analysis: €80 incl. VAT, personal reply within 24 hours.

100% confidential · Legal professional privilege · No obligation

Article generated by artificial intelligence, through a process designed and supervised by the firm

Sources: U.S. court opinions and official U.S. government publications, read for this article

Maître Hassan KOHEN, avocat au Barreau de Paris
Hassan KOHEN
Attorney at the Paris Bar

Propranolol Extended Release Capsules Metal Recall: Should You Keep Taking Them and What Are Your Rights?

Speak to a lawyer 06 89 11 34 45

On November 16, 2026, Breckenridge Pharmaceutical, Inc. announced a voluntary nationwide recall, at the consumer level, of one lot of propranolol hydrochloride extended-release capsules in the 60 mg strength, citing potential metal contamination. According to the company’s notice, the affected lot shared intermediate material with another lot, which was never released to the market, in which metal contamination was suspected, and capsules from the affected lot could potentially cause lacerations of soft tissues in the mouth, throat, esophagus, stomach, or intestine. The notice states that the affected lot was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 4, 2026, and that the company is not aware of any adverse events assessed as related to the recall. The discussion that follows is general in scope: it describes checks useful in comparable situations and makes no findings about Breckenridge’s situation. If you take propranolol, the questions are practical and immediate. Is your bottle part of the recalled lot, and how do you check? Should you keep taking the capsules? How do you obtain a replacement or a refund, and where do you report a problem? And when a generic prescription drug turns out to be contaminated, what does federal law actually say about who answers for it? This guide answers each of those questions from official sources: the company’s recall notice, the Food and Drug Administration’s recall guidance, the federal Food, Drug, and Cosmetic Act, and three decisions of the Supreme Court of the United States on prescription-drug liability, together with two June 2026 decisions of the Supreme Court of the United States and a September 2024 federal appellate decision applying them.

I. Propranolol Extended Release Capsules Metal Recall: Should You Keep Taking the Capsules?

The short answer, drawn directly from the recall notice, is that capsules from the affected lot should not be taken. The company’s notice instructs consumers to immediately stop taking product from the lot subject to the recall and to contact a physician or health care provider for medical advice and replacement instructions. That instruction concerns only the identified lot, not every bottle of propranolol, and the rest of this section explains how to tell the difference and what to do next.

A. How to Check Whether Your Bottle Belongs to the Recalled Lot

Start with the label on your own bottle. The recall covers a single lot: propranolol hydrochloride extended-release capsules, USP, 60 mg, in a 100-count bottle, National Drug Code 51991-817-01, lot number PK25110035, with an expiration date of May 2029. Those four elements together identify the recalled product: the drug name and strength, the package size, the NDC number, and the lot number. A bottle of propranolol with a different lot number is not part of this recall, even if the strength and appearance match, because the company’s notice limits the action to that one lot. If the pharmacy label on the outside of your bottle does not show the manufacturer’s lot number, the dispensing pharmacy can look it up in its dispensing records, since pharmacies track which manufacturer’s lot filled each prescription.

Two details in the notice deserve attention. First, the recall runs to the consumer level, meaning it reaches patients holding bottles at home, not only wholesalers and pharmacy shelves. The notice asks wholesalers, pharmacies, and other retail entities to check inventory for the recalled lot, quarantine any affected product, and stop distributing or dispensing it, and it asks distributors to notify their sub-accounts down to the retail level. Second, the distribution window is narrow: the affected lot went to wholesalers and pharmacies between October 26, 2026 and November 4, 2026, so prescriptions filled outside that window from other lots are outside the recall. If you filled a 60 mg extended-release propranolol prescription in late October or early November 2026, checking is worthwhile; if your bottle predates that period or carries a different lot number, the recall does not concern it.

Federal guidance frames what such a recall is. The Food and Drug Administration’s recall guidance explains that “A recall is an action taken by a company to correct or remove from the market an FDA regulated product that violates U.S. laws and regulations.” The same guidance adds that recalls “may be initiated voluntarily by a company, or at the request of the FDA,” which is exactly what happened here: the manufacturer announced the action itself at the consumer level. Metal contamination is one of the classic triggers the agency lists, since a common reason a product may be recalled is “The presence of foreign objects such as broken glass, metal fragments or plastic.” Under federal recall regulations, the Food and Drug Administration assigns each recall a numerical classification indicating the relative degree of health hazard, and the middle tier provides that “Class II is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” As of this writing, the classification of this particular recall had not yet appeared in the agency’s public enforcement database, so no class should be assumed; what matters for the patient is the company’s own warning about possible lacerations and its instruction to stop taking the affected capsules and call a physician or health care provider.

A final check concerns the medicine itself rather than the bottle. Propranolol is a beta blocker prescribed for conditions including high blood pressure, and patients should not adjust a heart or blood-pressure medicine on their own beyond what the recall notice and their own prescriber direct. The notice’s instruction has two parts of equal weight: stop the affected lot, and contact a physician or health care provider for medical advice and replacement instructions. A prescriber can confirm whether your bottle is affected, arrange a replacement supply from an unaffected lot, and decide whether any brief interruption or substitution is appropriate for your condition. Keep the bottle, including any remaining capsules, until the pharmacy or the prescriber tells you what to do with it, because the lot number on that bottle is the evidence that ties your prescription to the recall.

B. Replacement, Refund, and the Paper Trail to Keep

Once you have confirmed that your bottle carries lot PK25110035, the notice gives a clear next step: return any unused portion of the affected product to the pharmacy where it was obtained. The pharmacy is the point of return because distribution ran through wholesalers to pharmacies, and pharmacies hold the dispensing records that connect a patient to a lot. When you bring the bottle back, ask the pharmacist to confirm the lot number against the recall notice, to supply a replacement from a lot outside the recall, and to document the exchange in writing, including the date, the lot returned, and the lot dispensed as replacement. If the pharmacy no longer has unaffected stock in the same product, ask the prescriber to authorize an alternative supply so that treatment is not interrupted while the recall works through the distribution chain.

Money follows the same path as the medicine. A patient who paid for capsules that cannot be used is entitled to ask who absorbs that cost, starting with the dispensing pharmacy and following the chain the notice describes: the pharmacy obtained the product from a wholesaler, which obtained it under the manufacturer’s recall. Federal law supports the patient’s position at the foundation, because the Food, Drug, and Cosmetic Act treats a drug as adulterated “if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health,” and separately where “the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice.” Those are the standards of section 351 of Title 21 of the United States Code, which governs adulterated drugs and devices at the federal level. A metal-contaminated capsule sits squarely within the mischief that provision addresses, and that is why recalls of this kind happen: the product on the shelf does not meet the federal requirements for safety, identity, strength, quality, and purity. Whether a particular patient recovers the price of the bottle, the cost of a replacement, or related out-of-pocket expenses depends on state consumer and contract law applied to the receipts and records the patient kept, so keeping those records is itself part of the remedy.

The recall notice also imposes duties up the distribution chain that indirectly protect the patient. Wholesalers, pharmacies, and other retail entities must check their inventory for lot PK25110035, quarantine any affected product, and neither distribute nor dispense it, while any entity that further distributed the product must notify its own sub-accounts down to the retail level. In practice, that means a patient who reports an affected bottle triggers a documented quarantine and notification sequence behind the counter, and the written exchange record the patient requests at the pharmacy becomes part of that same sequence. If a pharmacy cannot supply a replacement from an unaffected lot, the prescriber remains the backstop for continuity of care, because only the prescriber can authorize a different strength, a different manufacturer's product, or a therapeutic alternative. Federal recall regulations contemplate exactly this kind of firm-initiated action, coordinated through the distribution chain to the consumer level, which is why the patient's prompt return of the bottle matters beyond the individual refund.

Reporting closes the loop and protects others. The Food and Drug Administration encourages patients, consumers, and health professionals to report problems with FDA-regulated products through its MedWatch safety program, which receives reports from the public and, when appropriate, publishes safety alerts for products including prescription medicines. Reports can be filed online, by phone, or by mailing or faxing the MedWatch form, and the agency also routes product-issue reports through its online Safety Reporting Portal. A patient who experienced mouth, throat, or digestive injury after taking capsules from lot PK25110035 should first seek medical care, then file a report describing the product by name, strength, NDC, and lot number, with dates of use and symptoms. Even a patient who suffered no injury performs a useful act by returning the bottle and confirming the lot, because each returned bottle helps the pharmacy and the recall administrator account for the stock distributed between October 26, 2026 and November 4, 2026. Keep copies of everything: the pharmacy receipt, the bottle label showing the lot number, photographs of the bottle and lot marking, the replacement prescription record, and any MedWatch confirmation. If a claim for compensation ever becomes necessary, that file, assembled in the first days after the announcement, is what connects the patient, the lot, and the injury.

II. Propranolol Recall and Your Rights: What Does Federal Law Say When a Generic Drug Is Contaminated?

Beyond the immediate steps, patients reasonably ask a harder question: if someone was harmed, who answers for a contaminated generic drug? Federal law gives a structured answer that took the Supreme Court of the United States three major decisions to build. The central thread is preemption, the constitutional rule that valid federal requirements displace conflicting state-law duties, and its application turns on whether the manufacturer is the brand company that wrote the label or a generic company that must copy it. Because propranolol extended-release capsules are marketed under their nonproprietary name rather than as a brand product, the generic-drug side of that line is the one that matters most here, and the decisions below explain why that distinction changes everything about failure-to-warn and design-defect claims.

A. Brand Labels, Generic Copies, and Why the Distinction Controls Lawsuits

The starting point is the manufacturer’s continuing responsibility for what the label says. In Wyeth v. Levine, 555 U.S. 555 (2009), decided March 4, 2009, the Supreme Court of the United States held that federal law does not preempt a state-law claim that a brand-name drug’s label gave an inadequate warning about a method of administration. The Court rejected the argument that the brand manufacturer could not comply with both the state-law duty and its federal labeling duties, explaining that the federal changes-being-effected regulation allowed the company to strengthen a warning unilaterally before obtaining agency approval. The opinion states the premise plainly: through successive amendments, “it has remained a central premise of federal drug regulation that the manufacturer bears responsibility for the content of its label at all times.” For the reader, the application is direct: the company that holds the approval for a drug owns the duty to keep its warnings adequate, and a patient harmed by an inadequate warning can invoke state tort law against the brand manufacturer without federal labeling law automatically closing the courthouse door.

Generic drugs play by a different federal rule, and that difference decided the next two cases. In PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), decided June 23, 2011, the Supreme Court of the United States held that federal drug regulations applicable to generic manufacturers directly conflict with, and thus preempt, state-law failure-to-warn claims against them. The reason is structural: federal law requires the manufacturer of a generic drug to use the same warning approved for the brand-name equivalent. Because the changes-being-effected process that saved the claim in Wyeth is, in the Court’s words, “not available for a generic drug” since its manufacturer cannot change the label without FDA approval, a generic company facing a state-law duty to add a stronger warning cannot independently do what state law requires while doing what federal law demands. Impossibility preemption follows: where it is impossible for a private party to comply with both state and federal requirements, the state claim gives way. In Merck Sharp & Dohme Corp. v. Albrecht, 587 U.S. 299 (2019), decided May 20, 2019, the Supreme Court of the United States refined the brand-side rule: clear evidence that federal law would have barred a stronger warning means proof that the maker fully informed the FDA of the justification for the warning and that the agency in turn refused the change, and whether that showing is made is a legal question for a judge rather than a jury.

Applied to a contamination recall, these holdings draw a map rather than a verdict. A claim that a generic manufacturer failed to warn about a contamination risk faces the Mensing barrier, because the generic label must match the brand label and the manufacturer cannot rewrite it unilaterally. A patient suing the brand-name sponsor whose label the generic copies may still lose if the sponsor proves, to a judge, clear evidence that the FDA would have rejected the stronger warning. But the map has open roads: claims against the brand-name sponsor whose label controls the generic copy, claims based on manufacturing and quality failures rather than warning language, and claims under state consumer-protection or warranty theories all stand on different footing that these three decisions do not close by themselves. The contamination itself remains governed at the federal level by the adulteration standards of section 351 of Title 21, which deem a drug adulterated when insanitary conditions may have contaminated it or when manufacturing controls depart from current good manufacturing practice. No court has applied any of this to lot PK25110035, and only a court deciding a filed case could say which of these roads a claim tied to this recall could travel.

B. What an Injured Patient Would Need to Show, Step by Step

New decisions keep applying that framework. On June 25, 2026, the Supreme Court of the United States decided Monsanto v. Durnell, No. 24-1068 (U.S. June 25, 2026), a pesticide-labeling preemption dispute in which the majority worked through the exception Bartlett had left open: where federal and state law both forbid selling a misbranded product, a manufacturer can comply with both by not selling it. For a patient holding contaminated capsules, the lesson is that parallel federal and state duties can reinforce rather than cancel each other when both regimes independently forbid the sale. A concurrence in the same decision invoked Wyeth, and a dissent applied Mensing’s impossibility test, confirming that all three drug-preemption landmarks still do live work on the Court’s current docket.

Three weeks earlier, on June 4, 2026, the Supreme Court of the United States decided Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 (U.S. June 4, 2026), a generic-drug case about skinny labels. Citing Mensing for the duty of sameness that binds generic manufacturers, the Court held that a generic maker that copies the brand label as the law requires — and truthfully calls its product a generic equivalent — cannot have that very compliance turned into building blocks for liability. For the reader, the application is concrete: a generic propranolol maker stands under the same duty of sameness the Court enforced in June 2026, so warning-based claims against the generic face the Mensing barrier while scrutiny shifts to the brand sponsor that controls the label and to manufacturing failures no label could excuse.

At the appellate level, the United States Court of Appeals for the Third Circuit decided In re Fosamax (Alendronate Sodium) Products Liability Litigation, No. 22-3412 (3d Cir. September 20, 2024), applying Albrecht’s clear-evidence framework to generic-drug warning claims and holding the state claims not preempted. For the reader, the application is practical: even years after the Supreme Court set the test, federal appeals courts still measure each failure-to-warn case against what the maker told the FDA and what the agency answered — the exact paper trail a patient’s pharmacy records, lot number, and adverse-event report help reconstruct.

For a patient holding a bottle from lot PK25110035, the practical sequence mirrors what courts examine. First, the product link: the bottle, the NDC 51991-817-01, and the lot number PK25110035, with the pharmacy’s dispensing record confirming that this patient received this lot during the October 26, 2026 to November 4, 2026 distribution window. Second, the medical link: prompt care for any mouth, throat, or digestive symptoms, a medical record connecting the symptoms to the capsules, and the prescriber’s assessment, since only a treating professional can evaluate injury and causation. Third, the paper link: the returned bottle or its photographs, receipts, the replacement prescription, and the MedWatch report, preserved together. Fourth, the legal link: identifying the proper defendant, which under the decisions above depends on who held the approval, who manufactured the lot, and who controlled the label, because the same injury produces different answers against a brand sponsor, a generic manufacturer, and a distributor. Time limits for state-law claims differ from state to state and are not decided by any source discussed here, so a patient considering a claim should determine the applicable state deadline promptly rather than assuming the recall itself pauses any clock. None of this guarantees any outcome; it describes the checks that make a later evaluation possible, and the evaluation itself belongs to a court applying the law of the patient’s state within the federal framework above.

Conclusion

The metal-contamination recall of one lot of propranolol extended-release 60 mg capsules gives patients a defined task: check the bottle for lot PK25110035 and NDC 51991-817-01, stop taking capsules from that lot as the notice directs, contact a physician or health care provider for replacement instructions, return the unused portion to the dispensing pharmacy with a written record of the exchange, and report any injury through MedWatch. Federal law treats a drug made under conditions that may have contaminated it as adulterated, assigns recalls a hazard classification, and places primary responsibility for label content on the manufacturer, while the Supreme Court’s brand-versus-generic preemption decisions determine which state-law claims can proceed against which companies. Those rules explain why the next steps are record-keeping and prompt medical and pharmacy follow-up rather than assumptions about liability, and they are the standards any future claim tied to this lot would have to meet.

📄 Official circular